Research programme: cell-based cancer immunotherapies - JW Biotechnology

Drug Profile

Research programme: cell-based cancer immunotherapies - JW Biotechnology

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator JW Biotechnology
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 07 Apr 2016 Early research in Cancer in China (unspecified route)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top